Dr Aadil Adnan

Dr. Aadil Adnan is a Consultant in Nuclear Medicine at Manipal Hospitals, E.M. Bypass, Kolkata, with more than five years of clinical and research experience in molecular imaging and targeted radionuclide therapies. He is skilled in high-dose radionuclide therapy for thyroid, prostate, neuroendocrine, and neural crest tumours, including targeted alpha therapies. He is proficient in performing and interpreting PET-CT and Gamma Camera scans, nuclear cardiology studies, and advanced theranostic procedures that integrate diagnostic imaging with precision-targeted treatment. His expertise also includes radiosynovectomy and minimally invasive radionuclide-based therapies.

Educational Qualifications:

• MBBS
• MD (Nuclear Medicine)

Memberships:

• Life Member, Society of Nuclear Medicine India (SNMI)
• Life Member, Association of Nuclear Medicine Physicians of India (ANMPI)
• Life Member, Federation of Head and Neck Oncology (FHNO)

Awards & Achievements:

• Panelist, Medullary Thyroid Carcinoma – NATCON 2019, Kolkata
• Attended Virtual Nuclear Cardiology Elective, ASNC (2020)
• Panelist, Multidisciplinary Management of Differentiated Thyroid Cancer Webinar (2020)
• Multiple participations in national CME and international conferences (IASO, Tata Memorial Centre, Medica, Dr. Reddy’s, FHNO, AONEI, Bengal Urological Society)
• Speaker at several academic forums between 2019–2024 on thyroid carcinoma, prostate cancer management, molecular imaging, and theranostics

Publications:

• Somatostatin Receptor Targeted PET-CT in Gastroenteropancreatic Neuroendocrine Neoplasms – Diagnostics, 2023
• PSMA Receptor-Based PET-CT: Clinical and Research Applications – Diagnostics, 2023
• Dual-Tracer PET-CT Imaging for Theranostics of Prostate Cancer – PET Clin, 2022
• Genetic Insight into Birt-Hogg-Dubé Syndrome in Indian Patients – Orphanet J Rare Dis, 2022
• 177Lu-DOTATATE PRRT in Metastatic Neuroendocrine Neoplasms – J Nucl Med Technol, 2021
• Multiple case reports and reviews on thyroid carcinoma, prostate cancer, PRRT, and neuroendocrine tumours